Anglo-Swedish drugmaker AstraZeneca said on Thursday it had been granted a temporary U.S. court order suspending sales of a generic version of its asthma drug Pulmicort by rival Teva.
Under the ruling, AstraZeneca and partner Par Pharmaceuticals will also suspend sales of their generic version of Pulmicort.
The restraining order remains in force until further order of the court. A preliminary injunction hearing is scheduled for Nov. 25 with a full court case due to start on Jan. 12.
AstraZeneca warned on Wednesday its full-year earnings would be at the lower end of its previously stated range as a result of the launch of generic Pulmicort, hammering its shares.